Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-040951
Filing Date
2023-11-14
Accepted
2023-11-14 14:22:13
Documents
43
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 706017
2 ex31-1.htm EX-31.1 17436
3 ex31-2.htm EX-31.2 17339
4 ex32-1.htm EX-32.1 8294
  Complete submission text file 0001493152-23-040951.txt   3652702

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE vicp-20230930.xsd EX-101.SCH 27892
6 XBRL CALCULATION FILE vicp-20230930_cal.xml EX-101.CAL 31060
7 XBRL DEFINITION FILE vicp-20230930_def.xml EX-101.DEF 138692
8 XBRL LABEL FILE vicp-20230930_lab.xml EX-101.LAB 248899
9 XBRL PRESENTATION FILE vicp-20230930_pre.xml EX-101.PRE 197360
37 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 441582
Mailing Address 1735 BUFORD HIGHWAY STE. 215-113 CUMMING GA 30041
Business Address 1735 BUFORD HIGHWAY STE. 215-113 CUMMING GA 30041 470-514-4013
Vicapsys Life Sciences, Inc. (Filer) CIK: 0001468639 (see all company filings)

EIN.: 621153426 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56145 | Film No.: 231404417
SIC: 2834 Pharmaceutical Preparations